Could RO7851624, newly into clinical trials, be RG6735?
ApexOnco Front Page
Recent articles
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
The company discontinues one of its two KRAS G12D degraders.
After a phase 3 push the livmoniplimab plan falters.
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
With a slashed valuation the newly listed biotech heads for phase 3.
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
An actinium-based backup and Werner helicase inhibitor are notable absences.
